Finland· FI-REL-REL10730

Synagis

A palivizumab product, registered in Finland by AstraZeneca AB. The same ATC class is registered in 13 of our 19 countries.

ATC J06BD01

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedSynagisATCJ06BD01REGISTER NO.FI-REL-REL10730PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Palivizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose

Palivizumab · ATC J06BD01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of palivizumab costs, country by country.

Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Palivizumab · price per daily dose (3.75 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$51.40
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Manufacturer
AstraZeneca AB
Country
Finland (FI)
ATC code
J06BD01
ATC class
Palivizumab
Defined daily dose
3.75 mg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/44f43e3c-e353-43c3-bcbd-261fa6b5b653
GET /v1/drugs/44f43e3c-e353-43c3-bcbd-261fa6b5b653?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "injektiokuiva-aine ja liuotin, liuosta varten",
  "route": "Lihakseen",
  "ddd_unit": null,
  "strength": "50 mg",
  "atc_label": "palivitsumabi",
  "ma_number": null,
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": "EU/1/99/117/001",
  "fimea_rel_id": "REL10730",
  "authorised_at": "1999-08-13"
}

See everything about palivizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.